#1 Clinical Trials Search in Europe

Ganciclovir Sodium

Ganciclovir Sodium is an antiviral medication that has been extensively studied in clinical trials for treating cytomegalovirus (CMV) infections, particularly in patients with weakened immune systems. These trials have explored its use alone and in combination with other drugs for conditions like CMV retinitis in AIDS patients and CMV infections in children. The research aims to optimize dosing, evaluate effectiveness, and assess safety across different patient populations.

Table of Contents

What is Ganciclovir Sodium?

Ganciclovir Sodium is an antiviral medication used to treat various viral infections, particularly those caused by cytomegalovirus (CMV). It’s also known by its brand name Cytovene[8]. This drug is primarily used in patients with weakened immune systems, such as those with AIDS or individuals who have undergone organ transplants.

What Conditions Does Ganciclovir Treat?

Ganciclovir is used to treat several conditions, including:

  • Cytomegalovirus (CMV) retinitis: An eye infection that can cause vision loss in people with weakened immune systems, particularly AIDS patients[1][2]
  • CMV viraemia: The presence of CMV in the bloodstream, often seen in immunocompromised children[3]
  • CMV encephalitis: An infection of the brain caused by CMV[4]
  • CMV radiculomyelopathy: An infection affecting the nerve roots and spinal cord[4]
  • CMV anterior uveitis/endotheliitis: Inflammation of the front part of the eye or the inner layer of the cornea caused by CMV[5][6]

How Does Ganciclovir Work?

Ganciclovir works by inhibiting the replication of the cytomegalovirus. It does this by interfering with the virus’s DNA synthesis, which is necessary for the virus to multiply. By stopping the virus from reproducing, ganciclovir helps to control the infection and prevent it from spreading further in the body[1].

How is Ganciclovir Administered?

Ganciclovir can be administered in several ways:

  • Intravenous (IV) infusion: This is the most common method for treating severe CMV infections. The dose is typically calculated based on the patient’s weight and kidney function[3].
  • Oral capsules: Used for maintenance therapy or less severe cases.
  • Intravitreal injections: Directly into the eye for treating CMV retinitis[1].
  • Topical gel or eye drops: Used for treating CMV infections of the eye[5][6].

Current Clinical Trials and Research

Several clinical trials are ongoing to improve the use of ganciclovir:

  • Individualized Dosing: A study called ID-MAGIC is investigating whether using a web app to customize ganciclovir doses for children with weakened immune systems can improve virus clearance compared to standard dosing[3].
  • Combination Therapy: Research is being conducted on combining ganciclovir with other antiviral drugs like foscarnet to improve efficacy in treating CMV retinitis[2][7].
  • Topical Applications: Studies are exploring the effectiveness of topical ganciclovir gels and eye drops for treating CMV infections of the eye[5][6].

Potential Side Effects and Precautions

Like all medications, ganciclovir can cause side effects. Some potential side effects include:

  • Blood disorders (anemia, low white blood cell count)
  • Kidney problems
  • Nausea and vomiting
  • Diarrhea
  • Fever

It’s important to note that ganciclovir can interact with other medications, particularly zidovudine (AZT), another antiviral drug often used in HIV treatment. Your doctor will carefully monitor your treatment and may adjust doses of medications to minimize risks[8].

Ganciclovir is a powerful tool in fighting CMV infections, especially in people with weakened immune systems. However, it requires careful administration and monitoring by healthcare professionals to ensure its safe and effective use.

Aspect Details
Primary Use Treatment of cytomegalovirus (CMV) infections in immunocompromised patients
Common Conditions Studied CMV retinitis in AIDS patients, CMV viraemia in immunocompromised children
Administration Methods Intravenous (IV), topical gel (for eye infections)
Dosing Approaches Standard dosing, personalized dosing using web apps
Combination Therapies Studied with Foscarnet, AZT (zidovudine)
Key Outcome Measures Virological clearance, disease progression, mortality, quality of life
Safety Considerations Monitoring for treatment-related adverse effects, drug resistance
Ongoing Research Focus Optimizing dosing regimens, improving treatment efficacy and safety

FAQ

  • What is Ganciclovir Sodium used to treat? Ganciclovir Sodium is primarily used to treat cytomegalovirus (CMV) infections, especially in patients with weakened immune systems. It has been studied for conditions like CMV retinitis in AIDS patients and CMV infections in immunocompromised children.
  • How is Ganciclovir Sodium administered? Ganciclovir Sodium can be administered in various ways depending on the specific condition and trial. It is commonly given intravenously (IV) but has also been studied as a topical gel for certain eye infections. Some trials have explored different dosing regimens, including standard dosing and personalized dosing approaches.
  • What are some of the potential side effects of Ganciclovir Sodium? While specific side effects weren't detailed in the provided trial information, antiviral medications like Ganciclovir can have various adverse effects. Clinical trials often monitor for treatment-related adverse effects. It's important to note that the safety profile can vary depending on the dosage, administration method, and individual patient factors.
  • How does Ganciclovir Sodium compare to other treatments for CMV infections? Several trials have compared Ganciclovir Sodium to other antiviral medications like Foscarnet, either alone or in combination. These studies aim to determine the relative effectiveness and safety of different treatment approaches for CMV infections, particularly in cases of retinitis or recurrent infections.
  • Are there ongoing studies to improve Ganciclovir Sodium treatment? Yes, there are ongoing efforts to optimize Ganciclovir Sodium treatment. For example, one recent trial (ID-MAGIC) is exploring the use of a web app to personalize Ganciclovir dosing in immunocompromised children, aiming to improve virus clearance rates compared to standard dosing methods.

Ongoing Clinical Trials on Ganciclovir Sodium

  • Study on Nanatinostat and Valganciclovir for Patients with Epstein-Barr Virus-Positive Relapsed or Refractory Lymphomas

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

Glossary

  • Cytomegalovirus (CMV): A common virus that can cause infection in people with weakened immune systems, potentially leading to serious complications like retinitis or other organ-specific diseases.
  • Retinitis: Inflammation of the retina, the light-sensitive tissue at the back of the eye. CMV retinitis is a serious condition that can lead to vision loss in people with AIDS.
  • Immunocompromised: Having a weakened immune system, which can be due to diseases like AIDS or medical treatments like chemotherapy, making a person more susceptible to infections.
  • Viraemia: The presence of viruses in the blood. In the context of these trials, it refers specifically to the presence of cytomegalovirus in the bloodstream.
  • Induction therapy: An initial, more intensive phase of treatment aimed at rapidly controlling the infection or disease.
  • Maintenance therapy: A less intensive, longer-term phase of treatment aimed at preventing recurrence or progression of the disease after initial control.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Polymerase Chain Reaction (PCR): A laboratory technique used to detect and measure the presence of specific genetic material, such as viral DNA, in a sample.
  • Anterior Uveitis: Inflammation of the front part of the eye, including the iris and nearby tissues.
  • Endotheliitis: Inflammation of the endothelium, the inner lining of blood vessels or, in the context of eye conditions, the inner layer of the cornea.

References

  1. https://clinicaltrials.gov/study/NCT00002156
  2. https://clinicaltrials.gov/study/NCT00000970
  3. https://clinicaltrials.gov/study/NCT06574789
  4. https://clinicaltrials.gov/study/NCT00000856
  5. https://clinicaltrials.gov/study/NCT01647529
  6. https://clinicaltrials.gov/study/NCT02943057
  7. https://clinicaltrials.gov/study/NCT00000665
  8. https://clinicaltrials.gov/study/NCT00002034